Zymeworks
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 277
- Market Cap
- $822M
- Introduction
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Zymeworks Sets Strategic Milestones for 2025-2026 with Focus on Novel Therapeutics
Zymeworks (ZYME) updates on strategic priorities for 2025-2026, including new drug applications for solid tumors, regulatory decisions, and clinical trial results. With FDA approval of zanidatamab and a focus on autoimmune diseases and hematological cancers, Zymeworks aims to strengthen its R&D pipeline and market position.
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
Zymeworks Inc. anticipates IND applications for ZW220 and ZW251 in 2025, and for ZW209 and ZW1528 in 2026. Phase 3 results for Ziihera® in HER2-positive GEA expected 2Q-2025, with potential sBLA submission. Regulatory decisions for zanidatamab in BTC in EU and China as early as 2Q-2025. Cash resources of $324M as of Dec 31, 2024, projected to fund operations into 2H-2027. Company to present at J.P. Morgan Healthcare Conference on Jan 16, 2024.
Zymeworks Outlines Strategic Priorities and Outlook for Future Developments
Zymeworks anticipates IND applications for ZW220 and ZW251 in 2025, and for ZW209 and ZW1528 in 2026. Phase 3 results for Ziihera® in HER2-positive GEA expected 2Q-2025, with potential sBLA submission. Regulatory decisions for zanidatamab in BTC expected as early as 2Q-2025. Cash resources of $324M as of Dec 31, 2024, projected to fund operations into 2H-2027. Company to present at J.P. Morgan Healthcare Conference on Jan 16, 2024.
Zymeworks Unveils 2025 Pipeline Strategy
Zymeworks plans IND applications for ZW220 and ZW251 in 2025, and ZW209 and ZW1528 in 2026. Anticipates Phase 3 HERIZON-GEA-01 results and sBLA for Ziihera® in 2025. Projects cash runway into 2H-2027 with $324M as of Dec 31, 2024. Aims to expand R&D into AIID and hematological cancers.
Cancer Immunotherapy Market Research Report 2025-2029
The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.
Zanidatamab likely to receive fast-track approval in Korea for HER2+ biliary tract cancer
Zanidatamab, the first HER2 bispecific antibody, received FDA accelerated approval for second-line biliary tract cancer. It shows improved response rates over existing treatments, offering new hope for HER2-positive patients. BeiGene plans to fast-track its approval in Korea, aiming for orphan drug designation.
FDA Approves New Biologic Cancer Treatments
Jazz Pharmaceuticals' ZIIHERA® approved for HER2-positive biliary tract cancer; Merus's BIZENGRI® approved for NRG1+ pancreatic adenocarcinoma and NSCLC; AstraZeneca's IMFINZI® approved for limited-stage small cell lung cancer and under Priority Review for muscle-invasive bladder cancer.
© Copyright 2025. All Rights Reserved by MedPath